5th Annual Tools/Dx Revolution: Insights From Our Thematic Panels

Research evidence excerpt

5th Annual Tools/Dx Revolution: Insights From Our Thematic Panels

line.kisa@tdsecurities.com

AI, with growing DTC and concierge channels creating meaningful commercial pathways.

William Ruby Panelists viewed multimodal, AI-enabled platforms that can integrate/interpret health data as

646 562 1325 enablers of earlier intervention, prevention, & health-span extension. Price & reimbursement

william.ruby@tdsecurities.com were the biggest levers to shift the market more into the mainstream.

Pradeep Ambrose, Ph.D. Long-Term Oncology Dx Roadmap: MRD is increasingly viewed as a foundational oncology

646 562 1378

tool, evolving from a niche application into a potential standard of care for recurrence

pradeep.ambrose@tdsecurities.com

monitoring, treatment selection, and future clinical trial design. Panelists emphasized that

highly sensitive testing, large longitudinal datasets, and AI-driven insights should accelerate

adoption. MolDX's approach to reimbursement should remain consistent (as policies & systems

are in place). Panelists and the audience expect consolidation (M&A) to play a bigger role in

the coming years.

Continued

AI Tools That Actually Move The Needle In Clinical R&D: AI is expected to drive meaningful

cost savings especially across trial design, site selection, patient recruitment, data collection,

and workflow productivity, but time savings are likely just as critical. Multimodal, provider-

connected data that can drive internal process improvements are seen as more valuable than

sheer size of discrete data sets alone.

Tools Platforms Capitalizing On Biopharma AI Demand: Panelists framed AI as much more of

a demand multiplier and volumes driver than a replacement risk, as models still require wet-

lab data, molecule build/test cycles, and validation.